Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17106304 | 1.00 | CYP1A2 (0.34) | CYP1A2CYP11B1CYP11B2 | |
| SCHEMBL17106303 | 1.00 | CYP1A2 (0.34) | CYP1A2CYP11B1CYP11B2 | |
| SCHEMBL17257515 | 0.69 | KCNH2 (0.30) | — | |
| SCHEMBL17257514 | 0.69 | KCNH2 (0.30) | — | |
| SCHEMBL19951605 | 0.68 | — | — | |
| SCHEMBL16620973 | 0.68 | — | — | |
| SCHEMBL16620975 | 0.68 | — | — | |
| SCHEMBL13562195 | 0.67 | MEN1 (0.33) | — | |
| SCHEMBL9845669 | 0.67 | KDM4E (0.32) | CYP1A2CYP11B1CYP11B2 | |
| SCHEMBL23294589 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3521409-B1 | PERFUME SYSTEMS | PROCTER & GAMBLE (US) | 2024-08-14 | — | — | EP | disclosed |
| EP-3521409-A2 | PERFUME SYSTEMS | The Procter & Gamble Company (US) | 2019-08-07 | — | — | EP | disclosed |
| EP-3122847-B1 | PERFUME SYSTEMS | PROCTER & GAMBLE (US) | 2019-05-15 | — | — | EP | disclosed |
| EP-3122847-B1 | PERFUME SYSTEMS | PROCTER & GAMBLE (US) | 2019-05-15 | — | — | EP | disclosed |
| EP-2928996-B1 | PERFUME SYSTEMS | PROCTER & GAMBLE (US) | 2018-04-11 | — | — | EP | disclosed |
| EP-2928996-B1 | PERFUME SYSTEMS | PROCTER & GAMBLE (US) | 2018-04-11 | — | — | EP | disclosed |
| EP-3122847-A1 | PERFUME SYSTEMS | The Procter & Gamble Company (US) | 2017-02-01 | — | — | EP | disclosed |
| EP-2928997-B1 | PERFUME SYSTEMS | PROCTER & GAMBLE (US) | 2017-01-25 | — | — | EP | disclosed |
| EP-2928997-B1 | PERFUME SYSTEMS | PROCTER & GAMBLE (US) | 2017-01-25 | — | — | EP | disclosed |
| US-20160289593-A1 | PERFUME SYSTEMS | PROCTER & GAMBLE (US) | 2016-10-06 | — | — | US | disclosed |
| US-20150267143-A1 | PERFUME SYSTEMS | PROCTER & GAMBLE (US) | 2015-09-24 | — | — | US | disclosed |
| US-20150267143-A1 | PERFUME SYSTEMS | PROCTER & GAMBLE (US) | 2015-09-24 | — | — | US | disclosed |
| US-20140161741-A1 | PERFUME SYSTEMS | THE PROCTER & GAMBLE COMPANY (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140161740-A1 | PERFUME SYSTEMS | THE PROCTER & GAMBLE COMPANY (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140161740-A1 | PERFUME SYSTEMS | THE PROCTER & GAMBLE COMPANY (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140161741-A1 | PERFUME SYSTEMS | THE PROCTER & GAMBLE COMPANY (US) | 2014-06-12 | — | — | US | disclosed |
| WO-2014089253-A1 | PERFUME SYSTEMS | THE PROCTER & GAMBLE COMPANY (US) | 2014-06-12 | — | — | WO | disclosed |
| WO-2014089254-A1 | PERFUME SYSTEMS | THE PROCTER & GAMBLE COMPANY (US) | 2014-06-12 | — | — | WO | disclosed |
| WO-2014089253-A1 | PERFUME SYSTEMS | THE PROCTER & GAMBLE COMPANY (US) | 2014-06-12 | — | — | WO | disclosed |
| WO-2014089254-A1 | PERFUME SYSTEMS | THE PROCTER & GAMBLE COMPANY (US) | 2014-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160289593-A1 | PERFUME SYSTEMS | TRPA1, PORCN, PLIN5 | CYP1A2 300/4885CYP11B1 2958/4885CYP11B2 2463/4885 |
| US-20150267143-A1 | PERFUME SYSTEMS | TRPA1, PORCN, PLIN5 | CYP1A2 300/4885CYP11B1 2958/4885CYP11B2 2463/4885 |
| US-20140161741-A1 | PERFUME SYSTEMS | TRPA1, PORCN, PLIN5 | CYP1A2 300/4885CYP11B1 2958/4885CYP11B2 2463/4885 |
| US-20140161740-A1 | PERFUME SYSTEMS | TRPA1, PORCN, PLIN5 | CYP1A2 300/4885CYP11B1 2958/4885CYP11B2 2463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.